AI Business is part of the Informa Tech Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
SRI International and Exscientia hope to accelerate the development of new cancer therapies
American nonprofit research center SRI International and Exscientia, a British AI-powered pharmatech company, are set to collaborate on a new approach to drug discovery.
The partners plan to accelerate drug discovery by integrating AI-based design with automated compound synthesis.
The project hopes to combine SRI’s automated synthetic-chemistry system SynFini with Exscientia’s AI-based Centaur Chemist to “expedite discovery of selective molecules for a high value oncology target,” according to the announcement.
“Both the SynFini and Centaur Chemist platforms have demonstrated ability to overcome key drug discovery challenges,” said Nathan Collins, chief strategy officer of SRI’s Biosciences Division and head of the SynFini program. “There is tremendous potential to further accelerate the oncology drug-discovery process by combining these novel and proven technologies.”
SRI’s SynFini platform was developed to speed up the process of bringing new drugs to market by accelerating chemical discovery and molecule development. The design, reaction screening and optimization (RSO), and production of target molecules are automated in the platform.
The SynFini system comprises a software platform, reaction screening platform and multi-step flow chemistry automation and development platform.
Earlier this year, SRI International teamed with French startup Iktos, which also specializes in AI for novel drug design.
The collaboration is focused on accelerating the discovery and development of anti-viral therapies, including therapies for COVID-19, according to an SRI spokesperson.
In the SRI-Exscientia venture, the companies are not disclosing any specific targets, other than they are in the oncology space.